Table 1.

Characteristics of eligible studies in this meta-analysis

ID	Year	Country	Sample size (high/low)	Cancer type	Method	Outcomes	HR availability	Follow-up months (mouth)	NOS Score
Zhu 2020 [35]	2020	China	60 (30/30)	Osteosarcoma	qRT-PCR	OS, PFS, CP	K-M curve	60	5
Lv 2019 [27]	2019	China	114 (58/56)	Cervical cancer	qRT-PCR	OS, PFS, CP	K-M curve	60	6
Wan 2016 [18]	2016	China	58 (27/31)	Lung cancer	qRT-PCR	OS, CP	K-M curve	60	6
Wang 2020 [28]	2020	China	67 (37/30)	Pancreatic ductal adenocarcinoma	qRT-PCR	OS, CP	K-M curve	60	6
Wu 2019 [26]	2019	China	73 (37/36)	Colorectal cancer	qRT-PCR	OS, CP	K-M curve	60	6
Wu 2020 [23]	2020	China	106 (70/36)	Osteosarcoma	qRT-PCR	OS, PFS, CP	K-M curve	60	6
Zhang 2020 [34]	2020	China	106 (53/53)	Bladder cancer	qRT-PCR	OS, PFS, CP	K-M curve	150	7
Xu 2018 [33]	2018	China	72 (36/36)	Gastric cancer	qRT-PCR	OS, CP	K-M curve	100	6
Shi 2018 [25]	2018	China	60 (31/29)	Lung cancer	qRT-PCR	CP	K-M curve	–	6
Kong 2019 [24]	2019	China	42 (18/24)	Ovarian cancer	qRT-PCR	CP	K-M curve	–	6

OS overall survival, PFS progression-free survival, CP clinicopathological parameters, NOS Newcastle–Ottawa Scale, K-M curve Kaplan–Meier curve, qRT-PCR quantitative real time polymerase chain reaction, -, not available or invalid